BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28176475)

  • 1. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
    Gately R; San A; Kurtkoti J; Parnham A
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():32-35. PubMed ID: 28176475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.
    Chua J; Paizis K; He SZ; Mount P
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():18-22. PubMed ID: 28176472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis.
    Kozlovskaya NL; Korotchaeva YV; Bobrova LA
    J Matern Fetal Neonatal Med; 2019 Sep; 32(17):2853-2859. PubMed ID: 29606012
    [No Abstract]   [Full Text] [Related]  

  • 5. A life-threatening case of pregnancy-related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab.
    Puri P; Hanxhiu A; O'Hara DV; Hsu D; Vucak-Dzumhur M
    BMC Nephrol; 2020 Nov; 21(1):488. PubMed ID: 33203373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.
    Carter S; Hewitt I; Kausman J
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():7-10. PubMed ID: 28176479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A; Nayer A; Haas CS
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.
    Servais A; Devillard N; Frémeaux-Bacchi V; Hummel A; Salomon L; Contin-Bordes C; Gomer H; Legendre C; Delmas Y
    Nephrol Dial Transplant; 2016 Dec; 31(12):2122-2130. PubMed ID: 27587606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.
    Okuda Y; Ishikura K; Terano C; Harada R; Hamada R; Hataya H; Ogata K; Honda M
    Nephrology (Carlton); 2016 Mar; 21(3):261-5. PubMed ID: 26818219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement.
    Hu H; Nagra A; Haq MR; Gilbert RD
    Pediatr Nephrol; 2014 Jun; 29(6):1103-6. PubMed ID: 24317637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
    Kim MJ; Lee H; Kim YH; Jin SY; Kim HJ; Oh D; Jeon JS
    BMC Nephrol; 2021 Mar; 22(1):86. PubMed ID: 33691638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.